Eris Lifesciences Acquires Novartis’ Zomelis (vildagliptin) in India for $13M

 Eris Lifesciences Acquires Novartis’ Zomelis (vildagliptin) in India for $13M

Eris Lifesciences Acquires Novartis’ Zomelis (vildagliptin) in India for $13M

Shots:

  • Eris Lifesciences acquired Novartis’ novel therapy Zomelis for $13M (~INR 93 crore) and will initiate the commercialization of product from Dec 10, 2019 in India
  • The acquisition of Zomelis will robust Eris Lifesciences’ presence with the enhancement of its diabetic portfolio in India and allow Eris to strengthen its products offering for patients with diabetes
  •  Zomelis is a therapy to treat type 2 diabetes and is the first innovator pharmaceutical product trademark acquisition by Eris. Additionally, Eris acquired Strides Shasun’ branded business portfolio to strengthen its footprints in the CNS segment for INR500 crore

Click here to­ read full press release/ article | Ref: Business Standards | Image: 1mg

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post